Drug Profile
HLX 22
Alternative Names: AC-101; HLX-22Latest Information Update: 19 Jan 2024
Price :
$50
*
At a glance
- Originator Alligator Bioscience
- Developer Shanghai Henlius Biotech
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Gastric cancer
- Phase I Solid tumours
Most Recent Events
- 18 Jan 2024 Efficacy and adverse events data from a phase II trial in Gastric cancer presented at Gastrointestinal Cancers Symposium 2024 (ASCO-GCS-2024)
- 17 May 2023 Efficacy, adverse events data from a phase I trial in solid tumours released by Shanghai Henlius Biotech
- 10 Feb 2023 Phase I clinical trial is still ongoing in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease) in China (IV) (NCT03916094)